Evidence map›Paper›PMID 42083883›Full record

ReviewObesity reviews : an official journal of the International Association for the Study of Obesity2026

GLP-1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms.

Giorgia Rutigliani, Tzu-Wen L Cross, Erica de Jong, Emily S Glover, Ivan D Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D Mattes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgia RutiglianiDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.ORCID https://orcid.org/0009-0004-5579-0617
Tzu-Wen L CrossDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Erica de JongDepartment of Food Science, Purdue University, West Lafayette, Indiana, USA.
Emily S GloverDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Ivan D MendozaDepartment of Human Development and Family Science, Purdue University, West Lafayette, Indiana, USA.
Mojisola AdisaDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Keigo TomooDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Xinyi ZhouDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Richard D MattesDepartment of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GLP-1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next-generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better characterization of their mechanisms of action. This narrative review critically assesses eight purported mechanisms including modulation of appetite, chemosensory function, cravings/aversions, food noise, gastric emptying, the microbiome, incretin activity, and energy expenditure. Current evidence does not support a single dominant mechanism; a combination of subtle effects may underlie the efficacy of these medications. However, as experience with these medications and methods to assess their effects grows, it should be possible to better determine the relative importance of these and possibly other mechanisms.

Indexed as

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityWeight LossAppetiteEnergy MetabolismGastric EmptyingGlucagon-Like Peptide-1 ReceptorHumansIncretinsAnti-Obesity AgentsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsappetitefood cravingsfood noisegastric emptyingmicrobiomesensory function

Identifiers

PMID42083883
PMCPMC13655938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.